INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), has recently sold a significant portion of its holdings in the pharmaceutical giant. According to a recent SEC filing, the endowment sold a total of 35,446 shares of Eli Lilly common stock on February 13, 2025. The shares were sold at prices ranging from $877.471 to $883.447 per share, amounting to a total transaction value of approximately $31.18 million.
Following this transaction, Lilly Endowment Inc. still retains a substantial stake in the company, holding 96,646,532 shares of Eli Lilly stock. The sales were executed in multiple transactions, with the endowment ensuring transparency about the range of prices at which the shares were sold. Based on the current trading price of $844.03, InvestingPro analysis indicates the stock is trading near its Fair Value, with 16 additional exclusive insights available to subscribers.
Lilly Endowment's continued substantial ownership in Eli Lilly highlights its sustained commitment to the company, even as it rebalances its investment portfolio. Investors will be watching closely to see how these sales might impact the company's stock performance in the coming days. With analyst price targets ranging from $620 to $1,190 and a consensus "Buy" recommendation, detailed analysis is available through InvestingPro's comprehensive research reports, which offer deep-dive analysis of the company's fundamentals and growth prospects.
In other recent news, pharmaceutical giant Eli Lilly has successfully issued $6 billion in new debt securities across six tranches, with maturities ranging from 2028 to 2065. The offering, managed by Barclays (LON:BARC) Capital Inc., BofA Securities, Inc., Citigroup (NYSE:C) Global Markets Inc., Deutsche Bank (ETR:DBKGn) Securities Inc., and Goldman Sachs (NYSE:GS) & Co. LLC, is expected to raise approximately $6.46 billion for general corporate purposes. Moody's (NYSE:MCO) Ratings has also upgraded Eli Lilly's issuer rating to Aa3 from A1, citing anticipated robust earnings growth driven by the company's incretin portfolio and blockbuster products. In addition, Bernstein research firm has reiterated an Outperform rating for Eli Lilly, with a price target of $1,100. Eli Lilly's drug Omvoh (mirikizumab-mrkz) has also shown sustained efficacy in Crohn's disease patients over two years of continuous treatment. These recent developments highlight Eli Lilly's strong financial foundation and commitment to innovation in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.